Ignite Creation Date:
2024-05-06 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 2:23 PM
Study NCT ID:
NCT05207722
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-02-16
First Post:
2022-01-12
Brief Title:
CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction GGEJ Adenocarcinoma
Sponsor:
Organization:
Celularity Incorporated